Nyxoah to Release Third Quarter Financial Results on

Nyxoah to Release Third Quarter Financial Results on November

Nyxoah to Release Third Quarter Financial Results on November

Mont-Saint-Guibert, Belgium

- October 18, 2022, 10:30pm CET / 4:30pm ET - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or

the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to

treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the third quarter of 2022

on Tuesday, November 8, 2022, after market close. Company management will host a conference call to discuss financial results that

day beginning at 10:30pm CET / 4:30pm ET.

Investors interested in listening to

the conference call may do so by registering for a unique personal PIN at the following link: https://register.vevent.com/register/BI0d7e0daed6e34e548b85e51146400c1a.

A live and archived webcast of the event will be available on the Company's investor relations website at https://investors.nyxoah.com/events.

Nyxoah is a medical technology company focused on the development

and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah's lead solution is the Genio system,

a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered

breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision

that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion

of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext

Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark

approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in

competitors' therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization

For more information, please visit http://www.nyxoah.com/.

Caution - CE marked since 2019. Investigational

device in the United States. Limited by U.S. federal law to investigational use in the United States.

Loic Moreau, Chief Financial Officer

Jeremy Feffer, VP IR and Corporate Communications